How To Save A Drug: Iressa’s Return Relied On Consistency Across Totality Of Evidence

 
• By Bridget Silverman
  
Generate a summary of this article
Listen to this article
Beta

Drug Review Profile of the second life of AstraZeneca’s Iressa shows how FDA adapts to imperfect but improving information without putting undue burden on sponsors – and how the agency recently applied a similar iterative approach to another EGFR inhibitor, Astellas and Genentech’s Tarceva.

FDA met the unusual circumstances of AstraZeneca PLC’s Iressa (gefitinib) in a genetically defined non-small cell lung cancer population – a new frontline NDA for a withdrawn third-line product – with an unconventional approach to the evidence, agency review documents show. Faced with a circumstance where the gold standard of two well-designed randomized trials would not be forthcoming, FDA looked for consistency of signals across an accretion of data.

Reviewers recognized problems with the trials underlying Iressa’s approval for first-line treatment of metastatic NSCLC with epidermal growth factor receptor...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Drug Review Profiles

More from Product Reviews

  • data

    New EU Filings

     
    • By Saba Afreen

    <p>Executive Summary</p> <p>Zanidatamab, Jazz and BeiGene’s investigational treatment for biliary tract cancer, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.</p>

  • data

    EU CHMP Opinions And MAA Updates

     
    • By Saba Afreen

    <p>Executive Summary</p> This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By Saba Afreen

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>